OSI PHARMACEUTICALS INC·4

Jun 7, 7:40 PM ET

LUNDEMOSE ANKER MD, PH.D, DSC 4

4 · OSI PHARMACEUTICALS INC · Filed Jun 7, 2010

Insider Transaction Report

Form 4
Period: 2010-06-03
LUNDEMOSE ANKER MD, PH.D, DSC
Exec. VP & Pres. OSI Prosidion
Transactions
  • Disposition to Issuer

    Common Stock

    2010-06-03$57.50/sh17,892$1,028,7901,675 total
  • Disposition from Tender

    Common Stock

    2010-06-03$57.50/sh11,056$635,72019,567 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh40,000$2,300,0000 total
    Exercise: $48.30Exp: 2015-03-07Common Stock (40,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh30,000$1,725,0000 total
    Exercise: $38.01Exp: 2012-06-14Common Stock (30,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh5,000$287,5000 total
    Exercise: $29.77Exp: 2013-06-12Common Stock (5,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh20,000$1,150,0000 total
    Exercise: $37.74Exp: 2013-12-12Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh22,000$1,265,0000 total
    Exercise: $47.29Exp: 2014-12-11Common Stock (22,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.52/sh48,000$2,760,9600 total
    Exercise: $33.62Exp: 2015-12-15Common Stock (48,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-06-03$57.50/sh20,000$1,150,0000 total
    Exercise: $35.40Exp: 2019-12-14Common Stock (20,000 underlying)
Footnotes (2)
  • [F1]Represents the number of unvested Restricted Stock Units that were canceled in exchange for a cash payment of $57.50 per unit in accordance with the Agreement and Plan of Merger, dated as of May 16, 2010, among OSI Pharmaceuticals, Inc., Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc.
  • [F2]These stock options were canceled in exchange for a cash payment in accordance with the Agreement and Plan of Merger, dated as of May 16, 2010, among OSI Pharmaceuticals, Inc., Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc. The cash payment made with respect to each stock option equals the product of (x) the number of shares issuable upon the exercise of such option multiplied by (y) the excess, if any, of $57.50 over the exercise price per share for such option.

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT